A5032461308- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Autoimmune Bullous Skin Diseases
- Dermatologic Treatments and Research
- Urticaria and Related Conditions
- Food Allergy and Anaphylaxis Research
- Pharmaceutical studies and practices
- Acne and Rosacea Treatments and Effects
- Nail Diseases and Treatments
- Spondyloarthritis Studies and Treatments
- Cytokine Signaling Pathways and Interactions
- Cutaneous lymphoproliferative disorders research
- Health Systems, Economic Evaluations, Quality of Life
- Nonmelanoma Skin Cancer Studies
- Contact Dermatitis and Allergies
- Skin Protection and Aging
- T-cell and B-cell Immunology
- Inflammatory Myopathies and Dermatomyositis
- Vascular Malformations and Hemangiomas
- Skin and Cellular Biology Research
- Wound Healing and Treatments
- Autoimmune and Inflammatory Disorders Research
- NF-κB Signaling Pathways
Université de Montréal
2004-2025
Centre Hospitalier Universitaire Sainte-Justine
2008-2025
Innovaderm (Canada)
2015-2024
Magna Graecia University
2023
Centre Hospitalier de l’Université de Montréal
2019-2023
Medical University of Graz
2018
Hôpital du Sacré-Cœur de Montréal
2017
McGill University
2013
Plastic Surgery Hospital
2013
Adult and Pediatric Dermatology
2013
BackgroundGBR 830 is a humanized mAb against OX40, costimulatory receptor on activated T cells. OX40 inhibition might have therapeutic role in cell–mediated diseases, including atopic dermatitis (AD).ObjectiveThis exploratory phase 2a study investigated the safety, efficacy, and tissue effects of GBR patients with AD.MethodsPatients moderate-to-severe AD (affected body surface area, ≥10%; Eczema Area Severity Index score, ≥12; inadequate response to topical treatments) were randomized 3:1 10...
Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. To compare clearance by the IL‐17A inhibitor ixekizumab IL‐23p19 guselkumab. IXORA‐R, a 24‐week, randomized, double‐blinded study, enrolled adults moderate‐to‐severe plaque [static Physician's Global Assessment of Disease (sPGA) score ≥ 3, Psoriasis Area Severity Index (PASI) 12, 10% body surface area]. were randomized (1 : 1)...
ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 Th17/Th22 pathways. The objectives this study were to evaluate efficacy, safety, pharmacokinetics effects systemic biomarkers patients with moderate‐to‐severe AD. Methods A total 36 AD randomized (3 : 1) or placebo phase Ib study. Three dosage cohorts studied over a 28‑day period (20 mg, 40 mg 80 once...
BackgroundAlopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant regrowth in AA.ObjectiveThe Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated the safety and efficacy oral JAK1/JAK2 inhibitor deuruxolitinib adult patients with AA.MethodsPatients aged 18-65 years ≥50% were randomized to 8 mg twice daily, 12 or placebo...
Abstract: Molluscum contagiosum is a common viral disease of childhood presenting as small, firm, dome‐shaped umbilicated papules. Although benign and generally self‐limited, this condition contagious can lead to complications such inflammation, pruritus, dermatitis, bacterial superinfection, scars. No consensus has been established concerning the management condition. We conducted prospective randomized study comparing four treatments for molluscum in 124 children aged 1 18 years. One group...
Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance.To investigate, a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety three doses mirikizumab (LY3074828), p19-directed IL-23 antibody, vs. placebo moderate-to-severe plaque psoriasis.Adult were randomized 1 : to receive (n = 52), 30 mg 51), 100 51) or 300 subcutaneously at weeks 0 8. The primary objective was evaluate superiority over achieving 90%...
Receptor‐interacting protein kinase 1 (RIPK1), a regulator of inflammation and cell death, is potential therapeutic target in immune‐mediated inflammatory diseases (IMIDs). The objective this phase IIa multicenter, randomized, double‐blind, placebo‐controlled study was to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, preliminary efficacy GSK2982772, RIPK1 inhibitor, plaque‐type psoriasis. Psoriasis patients ( N = 65) were randomized 60 mg twice daily (b.i.d.) or three...
Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan under investigation United States for treatment of atopic dermatitis (AD).To evaluate impact baricitinib plus background topical corticosteroids (TCS) on health-related quality life (HRQoL), how AD symptoms work productivity functioning, benefit using patient-reported outcome (PRO) assessments patients with moderate-to-severe previously experiencing inadequate response to...
An estimated 2–4% of Western populations are thought to have psoriasis, with a regional incidence ranging from 0.09% 11.43%. Variance in estimates is result differences study populations, methodology, differences, and definitions disease. Reliable prevalence plaque psoriasis challenging establish. Further, the distribution severity population unknown. This aims establish utility expert elicitation (EE) as method for estimating unknown parameters dermatology by (1) adult population, (2)...
Abstract Background There is a need for the development of novel non‐steroidal topical drugs treatment psoriasis. Objective To assess efficacy and safety 1.0% WBI‐1001 in patients with mild to moderate plaque Methods A total 61 1–10% body surface area (BSA) covered psoriasis physician’s global assessment score (PGA) 2–4 were randomized (2 : 1) receive either 1% cream formulation or placebo, applied twice daily 12 weeks. Efficacy was evaluated using PGA, BSA Psoriasis Area Severity Index...
Baricitinib, a selective Janus kinase 1/Janus 2 inhibitor, is indicated in the European Union and Japan for treatment of moderate-to-severe atopic dermatitis (AD) adults who are candidates systemic therapy. The objective this study was to evaluate safety baricitinib mg AD clinical program. Six double-blind, randomized, placebo-controlled studies, two long-term extension studies were summarized datasets. Placebo comparison based on six 16-week with mg. All-bari-2-mg-AD included patients...
Abstract Background In atopic dermatitis (AD), some studies have shown an association with increased cardiovascular disease in certain populations. However, other investigations found modest or no association. Despite conflicting results, molecular profiling both AD skin and blood demonstrated upregulation of atherosclerosis risk‐related markers. the underlying mechanisms connecting to vascular inflammation/atherosclerosis are unknown. this study, we aim determine factors associated...